Deepa Jewellers, Cotec Healthcare receive Sebi approval for IPOs Deepa Jewellers and Cotec Healthcare have received final observations from capital markets regulator Sebi to launch their IPOs, as primary market activity continues across jewellery and pharmaceutical manufacturing sectors.
Hyderabad-based Deepa Jewellers plans to raise funds through a combination of fresh issue and offer-for-sale.
The IPO consists of a fresh issue of shares worth up to Rs 250 crore and an offer for sale of up to 1.18 crore shares by promoters Ashish Agarwal and Seema Agarwal.
The company had filed its draft papers with Sebi in December 2025.
Incorporated in 2016, Deepa Jewellers operates as a business-to-business processor and supplier of hallmarked gold jewellery with a strong presence in southern India including Telangana, Karnataka, Andhra Pradesh, Tamil Nadu and Kerala.
The company primarily focuses on processing 22-karat gold jewellery and operates through an outsourced manufacturing model supported by around 40 karigars.
Its product portfolio includes traditional South Indian jewellery categories such as vaddanam, CNC machine-cut bangles, gents kada, vanki, kangan, earrings, mangtika, maatil, braid ornaments and rings.
Apart from jewellery processing, the company also undertakes job-work assignments where customers supply raw material and the company delivers finished ornaments.
Deepa Jewellers is also engaged in trading silver ornaments, gold bullion, precious stones and 18-20 karat jewellery products.
According to the company, it had a customer base of 315 clients across 13 states and one union territory as of November 2025, including jewellery retail chains and standalone jewellery stores.
The company’s business model is focused largely on wholesale distribution and processing rather than direct retail operations.
Separately, Cotec Healthcare also received Sebi approval for its IPO.
Cotec Healthcare operates as a contract development and manufacturing organisation, or CDMO, serving pharmaceutical companies across multiple therapeutic segments.
The company manufactures formulations across 24 dosage categories including injectables, tablets, capsules, ointments, syrups and infusions.
Its product portfolio spans therapeutic areas such as anaesthetics, antibiotics, cardiovascular drugs, dermatology, endocrinology, nutrition, supplements and women’s healthcare.
Cotec Healthcare operates a manufacturing facility in Roorkee spread across 21,871 square metres with installed manufacturing capacity of over 4 billion units.
The company serves domestic pharmaceutical companies and also exports products to 14 countries.
According to the company’s disclosures, it served 154 customers in FY25 compared with 177 in FY24 and 122 in FY23.
